Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Vaccinia Vaccine

A class of antineoplastic vaccines containing the vaccinia virus, originally used for immunization against smallpox, as a viral vector and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Purpose: Two viral oncoproteins, E6 and E7, are expressed in all human papillomavirus (HPV)–infected cells, from initial… Expand
2013
2013
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects
Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Development of a Listeria monocytogenes based vaccine against prostate cancer
Prostate specific antigen (PSA) is a likely immunotherapeutic target antigen for prostate cancer, the second leading cause of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2004
Highly Cited
2004
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC… Expand
Highly Cited
2003
Highly Cited
2003
Improved Assay To Detect Neutralizing Antibody following Vaccination with Diluted or Undiluted Vaccinia (Dryvax) Vaccine
ABSTRACT The assessment of immunogenicity of a diluted vaccinia vaccine for possible widespread use of a diluted vaccine in the… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
2003
2003
Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.
Since 1987, >10,000 individuals worldwide have received immunizations with human immunodeficiency virus (HIV) preventive vaccine… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
1997
Highly Cited
1997
Immunologic responses to vaccinia vaccines administered by different parenteral routes.
To develop a less reactogenic but equally immunogenic vaccine, this study of 91 human volunteers compared the safety and… Expand
  • figure 2
Highly Cited
1996
Highly Cited
1996
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.
Presentation of antigenic peptides by MHC class II molecules to CD4+ T cells is critical to the generation of antitumor immunity… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1996
Highly Cited
1996
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
Interleukin-2 (IL-2) has been an effective immune modulator in several active-specific immunotherapy experimental protocols using… Expand
  • table 2
  • figure 2
  • table 3
  • figure 3
  • figure 4
Highly Cited
1992
Highly Cited
1992
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
BACKGROUND Human carcinoembryonic antigen (CEA) is a 180-kd glycoprotein expressed in human colorectal, gastric, pancreatic… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE